Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Study Phase
Phase 3
Study Completion Date
May 2011
NCT00617669Uploaded 07-16-2020
Available for Download
PDS UID: Prostat_Multipl_2008_420
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer
PROTOCOLLinked Prostate_AstraZe_2008_104 Documentation.docx
CRFDataset Contents and Variable Crosswalk.xlsx
DATA DICTIONARYCODEBOOK_linked_prostate104.pdf
DATA SUMMARYProc Contents Data Dictionary Linked_Prostate104.pdf
DATA SUMMARYDescriptive_Stats_Linked_Prostat_AstraZe_2008_104.xlsx
DATA (COMPARATOR ARM)linked_prostate104.sas7bdat